Back to Journals » Infection and Drug Resistance » Volume 9

Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections

Authors Donnelley M, Zhu E, Thompson G

Received 7 January 2016

Accepted for publication 15 February 2016

Published 2 June 2016 Volume 2016:9 Pages 79—86

DOI https://doi.org/10.2147/IDR.S81416

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 3

Editor who approved publication: Professor Suresh Antony

Monica A Donnelley,1,2 Elizabeth S Zhu,1 George R Thompson 3rd3

1Department of Inpatient Pharmacy, University of California – Davis, Sacramento, 2Department of Clinical Sciences, Touro University College of Pharmacy, Vallejo, 3Department of Medicine, Division of Infectious Diseases, University of California – Davis, Davis, CA, USA

Abstract: We have a limited arsenal with which to treat invasive fungal infections caused by Aspergillus and Mucorales. The morbidity and mortality for both pathogens remains high. A triazole antifungal, isavuconazole, was recently granted approval by the US Food and Drug Administration and the European Medicines Agency for the treatment of invasive aspergillosis and mucormycosis. A randomized double-blind comparison trial for the treatment of invasive aspergillosis found isavuconazole noninferior to voriconazole. A separate, open-label study evaluating the efficacy of isavuconazole in the treatment of mucormycosis found comparable response rates to amphotericin B and posaconazole treated historical controls. The prodrug isavuconazonium sulfate is commercially available in both an oral and intravenous formulation and is generally well tolerated. Isavuconazole’s broad spectrum of activity, limited side effect profile, and favorable pharmacokinetics will likely solidify its place in therapy.

Keywords: isavuconazonium, antifungal, zygomycosis, mucor, mould infection, pharmacokinetics, pharmacodynamics, clinical efficacy, therapy, new agent

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Coccidioidomycosis: epidemiology

Brown J, Benedict K, Park BJ, Thompson GR III

Clinical Epidemiology 2013, 5:185-197

Published Date: 25 June 2013

Update on the optimal use of voriconazole for invasive fungal infections

Asma Lat George R Thompson III

Infection and Drug Resistance 2011, 4:43-53

Published Date: 3 February 2011